CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 22, 2019--
Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
constructs, announced a presentation at TIDES: Oligonucleotide and
Peptide Therapeutics, the world’s largest meeting to accelerate
oligonucleotide and peptide products from early discovery to late-stage
development and commercialization.
The talk, “Preclinical and Clinical Development of AST-008, A Toll-like
Receptor Agonist 9 Spherical Nucleic Acid for Immuno-oncology
Applications,” will be presented by Weston Daniel, Exicure Senior
Director of Program Management, at the conference, May 20-23 at
Manchester Grand Hyatt in San Diego.
Presentation Date/Time:Wednesday, May 22, 12:45 – 4:35 p.m. PT
Room:
Seaport A
Session: Oligonucleotide Discovery, Preclinical
and Clinical
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing
therapeutics for immuno-oncology, inflammatory diseases and genetic
disorders based on our proprietary Spherical Nucleic Acid, or SNA
technology. We believe Exicure's proprietary SNA™ architecture has
distinct chemical and biological properties that may provide advantages
over other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure's lead program is in a Phase1b/2 trial in patients
with advanced solid tumors. Exicure is based outside of Chicago, IL.www.exicuretx.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190522005036/en/
Source: Exicure, Inc.
MacDougall
Karen Sharma
781-235-3060
ksharma@macbiocom.com